OBGYN Chemo: Topotecan
I am an OBGYN resident, and this video is intended to briefly review the chemotherapeutic agent, Topotecan. This video is intended for medical students, residents, and fellows. Please enjoy!
Topotecan is a chemotherapy medication that is used in the treatment of various types of cancer. It belongs to the class of drugs known as topoisomerase inhibitors, which work by interfering with the DNA replication process in cancer cells.
Topotecan is primarily used for the treatment of ovarian cancer, small cell lung cancer, and certain types of cervical cancer. It can be administered orally in the form of capsules or intravenously through infusion. The drug is usually prescribed in combination with other chemotherapy agents or as a second-line treatment when other therapies have failed.
The mechanism of action of topotecan involves inhibiting an enzyme called topoisomerase I, which is essential for DNA replication and repair. By blocking this enzyme, the drug prevents cancer cells from dividing and growing, ultimately leading to their destruction.
Like other chemotherapy medications, topotecan can cause side effects, which may vary from person to person. Common side effects include nausea, vomiting, diarrhea, fatigue, decreased appetite, and low blood cell counts. It is important for patients to discuss these potential side effects with their healthcare provider and to seek medical attention if they experience severe or persistent symptoms.
Topotecan is available by prescription only and should be used under the guidance of a qualified healthcare professional. The dosage and treatment duration may vary depending on the type and stage of cancer being treated, as well as the individual patient's response to the medication. Regular monitoring and follow-up visits are necessary to assess the effectiveness of the treatment and manage any potential side effects.
Research on side effects:
Toxicity of weekly oral topotecan in relation to dosage for gynecologic malignancies: a phase I study. von Gruenigen et al., (2012) https://pubmed.ncbi.nlm.nih.gov/22555...
"The aim of this study was to determine the dose of weekly oral topotecan that allows safe administration and to evaluate the pharmacokinetics of this dose in patients with recurrent gynecologic malignancies. The first cohort of patients received oral topotecan 6 mg/week administered orally on days 1, 8, and 15 of a 28-day regimen. A standard 3 + 3 dose-escalating phase design was used for dose levels II–V (8, 10, 12 and 14 mg/week). Toxicity was scored according to the Common Terminology Criteria for Adverse Events. Cumulative toxicity was summarized in the 6–12 mg/week combined cohort and 14 mg/week cohort separately. Pharmacokinetic samples were obtained for day 1, cycle 1 only in the expansion cohort (dose level V). Twenty-five patients received a total of 88 cycles of therapy. Hematologic toxicities of grade 3 (6–12 mg dose) were neutropenia (25%) and anemia (8.3%). Gastrointestinal toxicities of grade 3 were diarrhea (16.7%) and obstruction (8.3%, disease-related). Grade 3 or 4 (14 mg/week) hematologic toxicities consisted of neutropenia (38.5%), platelets (15.4%), anemia (15.4%), infection with neutropenia (7.7%), and thrombosis (7.7%). Gastrointestinal toxicities of grade 3 were diarrhea (7.7%), obstruction (7.7%), and vomiting (7.7%). One patient died secondary to neutropenic sepsis. One patient (4%; 95% confidence interval: 2.1, 22.3) showed a partial response and five patients (20%; 95% confidence interval: 7.6, 41.3) had stable disease. An oral topotecan dose of 14 mg/week for 3 consecutive weeks out of 4 is mostly associated with acceptable toxicities and may be considered for use in future single-agent phase II trials."